title: [Analysis of 8-isoprostane concentration as a marker of oxidative stress in pregnant women diagnosed with IUGR].
abstract: Intrauterine growth restriction is connected with high rate of prematurity and perinatal mortality. 8-isoprostane is one of the oxidative stress indices, similar to the prostaglandins and connected with vessels restriction. The main aim of the study was to find the correlation between the L-arginine and acetylsalicylic acid therapy and 8-isoprostane concentration.
  
  
  METHODS
  The study was done in Dep. of Obstetrics and Gynaecology Medical University in Lodz in 2000-2002 y. The study group consist of 50 women with diagnosed IUGR, the controls: 30 healthy pregnant women at the same gestational age. The IUGR therapy consisted of L-arginine 3 x 1 g and acetylsalicylic acid--Acard 1 x 1 daily. 8-isoprostane was measured in maternal blood in first and 20-th day of observation. The Oxis Immunoassay for 8-epi prostaglandin was used. The results were expressed in ng/ml of serum.
  
  
  RESULTS
  The concentration of 8-isoprostane at the first day of observation in women with IUGR was 0.0587 ng/ml, and after 20 days decreased to 0.0569. In women in normal pregnancy at the first day was 0.0539 ng/ml and after 20 days 0.0547 ng/ml.
  
  
  CONCLUSIONS
  The 8-isoprostane concentration increased in blood serum due to the pregnancy duration. The therapeutic method decreased the concentration of this oxidative stress marker.
authors.affiliation: Kliniki Patologii Ciazy Instytutu Ginekologii i Połoznictwa UM w Łodzi.
authors.forename: Agata
authors.initials: A
authors.lastname: Karowicz-Bilińska
authors.forename: Urszula
authors.initials: U
authors.lastname: Kowalska-Koprek
authors.forename: Jacek
authors.initials: J
authors.lastname: Suzin
authors.forename: Piotr
authors.initials: P
authors.lastname: Sieroszewski
mesh_terms: D000328:Adult; D001120:Arginine / Q000008:administration & dosage; D001241:Aspirin / Q000008:administration & dosage; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D015237:Dinoprost / Q000031:analogs & derivatives*; D028441:F2-Isoprostanes / Q000097:blood*; D005260:Female; D005312:Fetal Blood / Q000378:metabolism; D005317:Fetal Growth Retardation / Q000097:blood* / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D009569:Nitric Oxide / Q000097:blood*; D019001:Nitric Oxide Synthase / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects; D011044:Poland; D011247:Pregnancy; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D028441:F2-Isoprostanes; C075750:8-epi-prostaglandin F2alpha; D009569:Nitric Oxide; D001120:Arginine; D015237:Dinoprost; D019001:Nitric Oxide Synthase; D001241:Aspirin